Add-on test to help classify pulmonary hypertension types now available in US
Distinguishing heart-related PH can guide proper treatment plans
Written by |
A noninvasive test that can help distinguish between different types of pulmonary hypertension is now available in the U.S. (Photo from iStock)
A noninvasive test that can help clinicians distinguish between different types of pulmonary hypertension (PH) is now commercially available in the U.S.
The test, dubbed the CorVista System Pulmonary Capillary Wedge Pressure (PCWP) Add-On, is an AI-powered add-on tool that can be used to help interpret signals from a point-of-care test that is offered by Corvista Health and Analytics 4 Life. The same system is already in use to help detect PH and other cardiovascular issues. The new add-on feature was cleared by U.S. regulators over the summer, and Corvista announced in a press release that the feature is now commercially available.
PCWP, the score measured by the new add-on test, is basically an estimate of the amount of pressure in the left atrium, the part of the heart that receives oxygen-rich blood from the lungs. High PCWP is a strong indicator of heart failure — meaning the heart is not effectively pumping blood throughout the body.
Different types of PH requires different treatments
PH refers to higher-than-normal pressure in the vessels that carry oxygen-depleted blood from the heart to the lungs. In PH associated with left-sided heart disease, one of the forms of PH, this pressure becomes elevated as a consequence of heart failure — essentially, the heart isn’t pumping out blood well, and blood becomes backed up in the lungs’ vessels as a consequence. But other forms of PH are unrelated to heart failure. For example, pulmonary arterial hypertension is driven by the abnormal growth of cells that line vessels in the lungs, causing these vessels to narrow.
Adding PCWP means more patients with suspected heart failure … can be identified earlier and routed to the appropriate care pathway.
Distinguishing between types of PH that are or are not associated with heart failure is crucial, because each of these different types of PH requires different treatments for effective management.
“Adding PCWP means more patients with suspected heart failure … can be identified earlier and routed to the appropriate care pathway,” said Charles R. Bridges, MD, executive vice president and chief scientific officer at Corvista.
Alongside the commercial launch of this add-on, Corvista also launched a Clinical Decision Support program, which aims to offer clinicians guideline-backed assistance in interpreting and implementing test results, taking into account factors like patients’ demographic background and symptoms.
“By combining established guideline-grounded recommendations with Corvista’s validated diagnostic performance, we give physicians a patient-specific probability of disease and a clear path forward,” Bridges said.
Adrian Lam, Corvista’s president and CEO, added: “Providing more data is not necessarily enough; a diagnostic result only creates value when it delivers actionable insights leading to the right next step in care. With clinical decision support and PCWP now in physicians’ hands, CorVista is helping health care teams provide accessible, guideline-driven care and act with confidence across [coronary artery disease], pulmonary hypertension and heart failure.”

Leave a comment
Fill in the required fields to post. Your email address will not be published.